[go: up one dir, main page]

MA32797B1 - Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one - Google Patents

Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one

Info

Publication number
MA32797B1
MA32797B1 MA33846A MA33846A MA32797B1 MA 32797 B1 MA32797 B1 MA 32797B1 MA 33846 A MA33846 A MA 33846A MA 33846 A MA33846 A MA 33846A MA 32797 B1 MA32797 B1 MA 32797B1
Authority
MA
Morocco
Prior art keywords
propylimino
thiazolidin
benz
ylidene
tolyl
Prior art date
Application number
MA33846A
Other languages
Arabic (ar)
English (en)
Inventor
Nicholas Bonham
Stephan Buchmann
Alex Eberlin
Christoph Imboden
Raumer Markus Von
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40097688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32797(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA32797B1 publication Critical patent/MA32797B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMES CRISTALLINES DE LA (R)-5[3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)- BENZ-[Z]-YLIDÈNE]-2-([Z]-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE, DES PROCÉDÉS POUR LEUR PRÉPARATION, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITES FORMES CRISTALLINES, ET LEUR UTILISATION COMME COMPOSÉS AMÉLIORANT LA FONCTION VASCULAIRE ET COMME AGENTS IMMUNOMODULATEURS, SOIT SEULS, SOIT EN ASSOCIATION AVEC D'AUTRES COMPOSÉS ACTIFS OU THÉRAPIES.
MA33846A 2008-10-20 2011-05-13 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one MA32797B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819182.7A GB0819182D0 (en) 2008-10-20 2008-10-20 Crystalline forms
PCT/IB2009/054592 WO2010046835A1 (fr) 2008-10-20 2009-10-19 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl-thiazolidin-4-one

Publications (1)

Publication Number Publication Date
MA32797B1 true MA32797B1 (fr) 2011-11-01

Family

ID=40097688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33846A MA32797B1 (fr) 2008-10-20 2011-05-13 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one

Country Status (27)

Country Link
US (1) US9062014B2 (fr)
EP (1) EP2344465B1 (fr)
JP (1) JP5008777B2 (fr)
KR (1) KR101409597B1 (fr)
CN (1) CN102177144B (fr)
AR (1) AR073904A1 (fr)
AU (1) AU2009305980C1 (fr)
BR (1) BRPI0919673B1 (fr)
CA (1) CA2740313C (fr)
CL (1) CL2011000867A1 (fr)
CY (1) CY1116118T1 (fr)
DK (1) DK2344465T3 (fr)
ES (1) ES2534333T3 (fr)
GB (1) GB0819182D0 (fr)
HR (1) HRP20150391T1 (fr)
IL (1) IL212351A (fr)
MA (1) MA32797B1 (fr)
MX (1) MX2011003988A (fr)
MY (1) MY160703A (fr)
NZ (1) NZ592854A (fr)
PL (1) PL2344465T3 (fr)
PT (1) PT2344465E (fr)
RU (1) RU2519548C2 (fr)
SI (1) SI2344465T1 (fr)
TW (1) TWI462911B (fr)
WO (1) WO2010046835A1 (fr)
ZA (1) ZA201103691B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352555T3 (es) 2003-11-21 2011-02-21 Actelion Pharmaceuticals Ltd. Derivados de 5-(benc-(z)-iliden)tiazolidin-4-ona como agentes inmunosupresores.
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
EP2489662B1 (fr) * 2006-11-23 2014-08-06 Actelion Pharmaceuticals Ltd. Intermédiaires d'un nouveau procédé pour la préparation de dérivés de 5-benzylidène-2-alkylimino-3-phénylthiazolidin-4-one
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
HRP20170246T4 (hr) 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora
KR102038048B1 (ko) * 2011-06-02 2019-10-30 키노인 제트알티. 프로스타글란딘 아미드의 신규한 제조 방법
JP6322630B2 (ja) 2012-08-17 2018-05-09 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
MY188764A (en) 2014-12-11 2021-12-30 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
US10487064B1 (en) 2015-12-25 2019-11-26 Crystal Pharmatech Co., Ltd. Crystalline forms of selective S1P1 receptor modulator and preparation method thereof
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11220488B2 (en) 2017-09-19 2022-01-11 Teva Pharmaceuticals International Gmbh Crystalline polymorph of Ponesimod
US11186556B1 (en) * 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
BR112022001138A2 (pt) 2019-07-22 2022-03-15 Actelion Pharmaceuticals Ltd Métodos de tratamento de esclerose múltipla
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
WO2021143414A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de ponesimod, son procédé de préparation et son utilisation
IL295976A (en) 2020-03-06 2022-10-01 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
US20240368094A1 (en) 2021-08-17 2024-11-07 Teva Czech Industries S.R.O Polymorphs of ponesimod
US12357616B2 (en) 2021-10-11 2025-07-15 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
US20230144895A1 (en) 2021-10-11 2023-05-11 Actelion Pharmaceuticals Ltd Methods Of Treating Multiple Sclerosis
CA3220715A1 (fr) 2021-10-11 2023-04-20 Krista Spiller Methodes de traitement de la sclerose en plaques
EP4415699A1 (fr) 2021-10-11 2024-08-21 Laboratoires Juvise Pharmaceuticals Méthodes de traitement de la sclérose en plaques
EP4426296A1 (fr) 2021-11-05 2024-09-11 Actelion Pharmaceuticals Ltd Méthodes de traitement de la sclérose en plaques
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p
CA3220702A1 (fr) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methodes de ralentissement d'une augmentation du volume ventriculaire cerebral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79793C2 (en) * 2002-07-10 2007-07-25 Applied Research Systems Azolidinone-vinyl fused-benzene derivatives
WO2005037424A1 (fr) * 2003-10-06 2005-04-28 Solvias Ag Procede pour la detection en parallele des formes cristallines de solides moleculaires
USRE43833E1 (en) * 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
ES2352555T3 (es) 2003-11-21 2011-02-21 Actelion Pharmaceuticals Ltd. Derivados de 5-(benc-(z)-iliden)tiazolidin-4-ona como agentes inmunosupresores.
EP2489662B1 (fr) 2006-11-23 2014-08-06 Actelion Pharmaceuticals Ltd. Intermédiaires d'un nouveau procédé pour la préparation de dérivés de 5-benzylidène-2-alkylimino-3-phénylthiazolidin-4-one
US8912340B2 (en) * 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
HRP20170246T4 (hr) 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora

Also Published As

Publication number Publication date
EP2344465B1 (fr) 2015-01-07
RU2011119898A (ru) 2012-11-27
NZ592854A (en) 2013-01-25
CA2740313A1 (fr) 2010-04-29
TWI462911B (zh) 2014-12-01
BRPI0919673A2 (pt) 2020-09-15
HRP20150391T1 (hr) 2015-05-22
CN102177144B (zh) 2014-12-31
DK2344465T3 (en) 2015-02-16
PT2344465E (pt) 2015-04-23
MX2011003988A (es) 2011-05-10
IL212351A0 (en) 2011-06-30
BRPI0919673B1 (pt) 2022-02-08
TW201022220A (en) 2010-06-16
CL2011000867A1 (es) 2011-09-23
KR101409597B1 (ko) 2014-06-20
AU2009305980C1 (en) 2015-01-22
US20110196004A1 (en) 2011-08-11
AU2009305980A1 (en) 2010-04-29
JP2012505873A (ja) 2012-03-08
HK1159624A1 (en) 2012-08-03
PL2344465T3 (pl) 2015-06-30
ZA201103691B (en) 2015-12-23
AU2009305980B2 (en) 2014-10-02
CA2740313C (fr) 2016-09-27
KR20110071133A (ko) 2011-06-28
AR073904A1 (es) 2010-12-09
JP5008777B2 (ja) 2012-08-22
IL212351A (en) 2015-09-24
CY1116118T1 (el) 2017-02-08
ES2534333T3 (es) 2015-04-21
SI2344465T1 (sl) 2015-04-30
EP2344465A1 (fr) 2011-07-20
MY160703A (en) 2017-03-15
GB0819182D0 (en) 2008-11-26
RU2519548C2 (ru) 2014-06-10
US9062014B2 (en) 2015-06-23
WO2010046835A1 (fr) 2010-04-29
CN102177144A (zh) 2011-09-07

Similar Documents

Publication Publication Date Title
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
EP2350054A4 (fr) Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CL2014000270A1 (es) Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010).
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
CR20120295A (es) Triazolopiridinas
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201070853A1 (ru) Кристаллический (r)-2-(4-циклопропансульфонилфенил)-n-пиразин-2-ил-3-(тетрагидропиран-4-ил)пропионамид
UY31688A1 (es) Plaguicidas
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
SE0800742L (sv) Vikttäcke
UA94603C2 (ru) Производные тетрагидронафталина, способ их получения и их применения в качестве ингибиторов воспаления
CL2007003066A1 (es) Metodo de obtencion de derivados de 8-fenil-cromanos por reduccion de la correspondiente amida.
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
NI200900154A (es) Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
ITRM20080037A1 (it) Procedimento per la ultrapurificazione di alginati.
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина